Inicio >> Noticias

Chemotherapy of advanced gastric cancer.

Rivera F, Vega-Villegas MA, Lopez-Brea MF

Servicio de Oncologia Medica, Hospital Universitario Marques de Valdecilla, Avda. Valdecilla, s/n 39008 Santander, Spain.

Gastric cancer is the second most frequent cancer in the world. Approximately 84% of patients with gastric cancer will have advanced disease and median survival of these patients without chemotherapy is only 3-4 months. "Classical" chemotherapy regimens, mainly CF (cisplatin plus infusional 5FU) and ECF (cisplatin plus infusional 5FU plus Epirubicin) obtain responses in 20-40% of the patients and improve quality of life. Nevertheless, duration of these responses is short with very few complete responses. Median time to tumor progression (TTP) with these regimens is only about 4-5 months and median survival does not exceed 7-10 months. Moreover, benefit seems to be limited to patients with good performance status and treatment toxicity and discomfort are not negligible, specially that of regimens with cisplatin or infusional 5FU. Trying to improve these results, the incorporation of new drugs has been explored. Among the new combinations, the more developed ones are those with Docetaxel (DCF), oxaliplatin (EOX, FLO), Capecitabine (EOX, cisplatin-Xeloda) and irinotecan (ILF). We have final results from Phase III trials that suggest that all these regimens could have a role in the treatment of these patients but survival is still very poor and toxicity remains important. It would be interesting to investigate other new combinations and the incorporation of drugs directed against new therapeutic targets in this setting. It would be of utmost interest that these clinical trials would also explore clinical and molecular prognostic and predictive factors.

PMID: 17376598 [PubMed - as supplied by publisher]






 

 

 






Otras Noticias...

La Hormona Obestatina Puede Revolucionar La Pérdida De Peso.

Solo Uno De Cada 10 Profesores Universitarios Tiene Doctorado.

Un Paseo Por El Arte.

¿Chile Ha Perdido Su Rumbo Dentro Del Grupo Apec?.

Pensando En El Postgrado En Endosonografía.

Formarse Toda La Vida.

Yo Hice Un Postgrado.

Caminar: Una Opción Sana Y Segura Para Nuestras Tardes.

Grandes Salmoneros Dan Alto En Inversión Y Chile Elevará Los Envíos En Un 50% El 2010.

Charlas Educativas En Hospital De Mulchén.

Presentación Primer Caso De Paciente Con Pseudoquiste De Baja Data De Evolución.

Enfermedad Celiaca.

La Fibra Que Nos Limpia.

Pancreatitis crónica podría incrementar el riesgo de desarrollar cáncer de páncreas.








 

Google